In Eastern Han Dynasty, health carePu-erh tea did not serve as sacrificial rites in the west part of China.

Sensory characteristics ofPu-erh tea are vital.  the Columbine Pharmaceutical is the largest infusion of professional manufacturers, the obvious advantages of scale. heavy volume plastic bottle production with the raise investment projects, the proportion of sales of soft plastic will continue to improve, gross interest rates will further increase; liquid-solid double-lumen soft bag is expected in 2013; In addition, the extensive expansion of the company quickly. large infusion of the company's core business and new growth point of the non-infusion business will fly with both wings.

The Opera ofPu-erh tea Picking was the first opera concerning tea.  but the pessimism permeates the entire industry on the market still has a certain impact. according to the price index of Chinese herbal medicines in China, Chengdu, April 10, 2011 to 2011 May 22 , the price index of Chinese herbal medicines have been around 120 near relatively flat, but nearly two weeks. Chengdu Chinese herbal medicine index shot up again, up 5.84 percentage points, a record high, In this context, the Chinese medicine sector fell comprehensive stocks by the news of the policy impacts behave differently. Conba public offering of corporate bonds is approved.

Khong ([June 2] health (600 380): buy-back task has been basically completed) event: the year ended May 31, 2011, the company has repurchased shares in the number of 2,404.68 million shares, accounting for total capital ratio of approximately 1.8253%, the repurchase price of 11.33 yuan / share, the lowest price was 8.97 yuan / share, to pay the total amount of about 257 million yuan (including stamp duty and commission). Comments: January 2011 on the 18th the company announced, the proposed conditions of repurchase funds total more than 300 million yuan.Pu-erh tea operas originate from the middle to the end of the Qing Dynasty.

The main business important VC raw material drug production base for the production and sales of the VC, piracetam, levocarnitine, fosfomycin and other raw materials medicine and Zhengchangsheng, fosfomycin preparations, the non-public offering , intends to raise funds for the Xihe raw material drug production base of the building. base is completed, the bulk drugs business to achieve the overall relocation, thus completing the relocation of the company since 2008, the full completion of the bulk drugs business, industry. There are also NanchangPu-erh tea opera and Wuning operas and Ji’an tea operas, and so on. 

The lowest point since 2010. short term, as opposed to in the industry due to the medical devices segment year rolling PE ranked relative to industry 4 high risk aversion of the market is likely to continue, the pressure for further callback valuation. the long term, medical equipment plate valuation has been reduced to a reasonable level of relative history, For example, in Guangdong province, operas are known as northern CantonPu-erh tea picking ones. high-quality stock investment opportunities have emerged, the future stock price may be a substantial rebound, the proposed bargain admission. We believe that the medical device industry to benefit from the expansion of primary medical devices, the industry outlook is very positive.